Press Release Description

Advancements in Liquid Biopsy: Revolutionizing Early Cancer Detection & Treatment

The EMEA Liquid Biopsy Market is projected to grow at a CAGR of around 13.98% during the forecast period of 2023-28, cites MarkNtel Advisors in the recent research report. The prevalence of cancer cases in the EMEA region has been attributed to factors like sedentary lifestyles & exposure to harmful carcinogens in the environment. This has raised public awareness about the importance of early cancer detection & treatment. In response, healthcare institutions are developing liquid biopsy tests to detect cancer markers at an early stage. Hence, these advancements have led to a growing demand for liquid biopsy in the region. Liquid biopsy assures improving cancer treatment by allowing early detection & monitoring of tumor-related genetic material, such as circulating tumor DNA (ctDNA). Owing to these benefits, medical researchers across the region are exploring the usage of ctDNA to identify early symptoms & detect tumors in the bloodstream. For example, GRAIL (Gene recognition and analysis internet link) has developed a multi-cancer blood test based on DNA methylation patterns in ctDNA to identify & treat cancer at earlier stages.

Additionally, this technique allows for the possibility of moving drugs, currently being tested in late-stage cancer to early-stage disease, contributing to more effective cancer treatment. The utilization of liquid biopsy has been expanded to identify the most effective therapies for cancer patients, particularly those with lung & prostate cancer, who are prescribed targeted drugs. As a result, enriched investments from government organizations & pharmaceutical companies in the research & development of novel cancer treatments are presumed to enhance the growth of the EMEA Liquid Biopsy Market.

Moreover, the expansion of the market is influenced by the adoption of advanced technologies such as polymerase chain reaction (PCR) & next-generation sequencing (NGS), as these technologies provide fast & accurate results, reducing the likelihood of false outcomes. Consequently, clinicians often choose these methods & recommend them to patients, further, the wide adoption of this technique is likely to fuel market growth during the forthcoming period, reveals MarkNtel Advisors in their research report, "EMEA Liquid Biopsy Testing Analysis, 2023."

EMEA Liquid Biopsy Market

Circulating Tumor DNA to Gain Noticeable Traction in the Upcoming Years

Based on circulating biomarkers, the market is further bifurcated as Circulating Tumor Cell (CTC), Circulating Tumor DNA (CTDNA), Cell-Free DNA (CFDNA), and Extracellular Vesicle (EVS). Of them, the Circulating Tumor DNA (CTDNA) is gaining notable momentum in the EMEA Liquid Biopsy Market. Rising advancements in cancer research & diagnostics due to the increasing prevalence of cancer cases, the need for non-invasive, and the growing requirement for efficient methods of detecting & monitoring tumors are the key factors leading to higher adoption of CTDNA testing. Several prominent companies, such as Roche Diagnostics, Illumina, Guardant Health, etc., are actively involved in the development & commercialization of CTDNA-based technologies in the EMEA region. Moreover, the cost competitiveness of CTDNA & its advantage in early cancer detection is further augmenting its demand among end-users.

Germany to Witness Substantial Growth in the Upcoming Years

Geographically, Germany has the highest contribution to the growth of the EMEA Liquid Biopsy Market due to the presence of large-scale leading players in the country, such as Roche, Qiagen N.V., and others. High cancer prevalence, rise in R&D activities of cancer research, and increasing options for innovation in liquid biopsy tests reinforce the growth of the national market. The country is also expanding research activities through an upsurge in a government initiative to modernize the healthcare infrastructure & expenditure. Strategic approvals & collaboration between major market players to promote liquid biopsy technology in the region are also projected to propel the market growth in the forecast years.

Competitive Landscape

With strategic initiatives, such as mergers, collaborations, and acquisitions, the leading market players, including Thermofisher Scientific, Hoffmann-La Roche Ltd, Sysmex Corporation, Qiagen N.V., Guardant Health, Bio Rad, Neo Genomics, Epigenomics, Menarini-Silicon Biosystems, Agena Bioscience Inc., Silicon Biosystems, Pathway Genomics Corporation, Illumina Inc., Myraid Genetics, and others are looking forward to strengthening their market position.

Key Questions Answered in the Research Report

  1. What are the industry’s overall statistics or estimates (Overview, Size- By Value, Forecast Numbers, Segmentation, Shares)?
  2. What are the trends influencing the current scenario of the market?
  3. What key factors would propel and impede the industry across the region?
  4. How has the industry been evolving in terms of geography & product adoption?
  5. How has the competition been shaping across various countries?
  6. How has the buying behavior, customer inclination, and expectations from product manufacturers been evolving during 2018-28?
  7. Who are the key competitors, and what strategic partnerships or ventures are they coming up with to stay afloat during the projected time frame?

Place an order
Only market data will be provided in the excel spreadsheet.

USD 3,100
USD 2,480

The report will be delivered in PDF format without printing rights. It is advised for a single user.

USD 3,950
USD 3,160

The report will be delivered in PDF format with printing rights. It is advised for up to five users.

USD 4,850
USD 3,880

The report will be delivered in PDF format with printing rights and excel sheet. It is advised for companies where multiple users would like to access the report from multiple locations

USD 6,350
USD 4,450

Need Assistance?

WRITE AN EMAIL

[email protected]
100% Safe & Secure

Strongest encryption on the website to make your purchase safe and secure